glaucoma

How surveillance studies help address antibiotic resistancePenny Asbell, MD, explains the latest research findings from the Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) study.
Glaucoma patients' gender plays a role in treatmentsLouise A. Sclafani, OD, FAAO, talks about the different concerns with men and women when diagnosing and treating glaucoma patients at Vision Expo West in Las Vegas, NV.
Medically managing glaucoma
Medically managing glaucomaOptometry Times Editorial Advisory Board member Leo P. Semes, OD, FAAO, sits down to talk about managing glaucoma, treatment recommendations, intraocular pressure, and new medications in treating glaucoma at Vision Expo West in Las Vegas, NV.
Corneal hysteresis indicator for glaucoma progression
Corneal hysteresis indicator for glaucoma progressionJustin Schweitzer, OD, in Sioux Falls, SD, examines corneal hysteresis and discusses how it may be an indicator for glaucoma progression in patients at Vision Expo West in Las Vegas, NV.
How to achieve a calm, stress-free ORAchieving the best visual outcomes in challenging cases is a high priority in surgical retina. However, meeting that goal involves a high level of creativity, especially in complex cases associated with other ocular comorbidities.
Progression of visual field loss not always easy to test, analyzeAssessing visual field progression in glaucoma may be more of an art than a science—and there is no one test to give reliable information that is needed about a patient, said Chris A. Johnson, PhD, DSc, FAAO, FARVO, professor, Department of Ophthalmology, and director, Visual Field Reading Center, University of Iowa, Iowa City.
Neuroprotective strategy primed for progress
Neuroprotective strategy primed for progressAdvancing methods for evaluating therapeutic response have fostered a new era in glaucoma neuroprotection in which promising candidates are already being investigated in clinical trials and others are poised to begin phase I testing, said Jeffrey L. Goldberg, MD, PhD.
Fixed-combination glaucoma agent yields positive safety, efficacy dataA phase III trial for the fixed-combination netarsudil/latanoprost agent (Roclatan, Aerie Pharmaceuticals)reports positive results. The company plans to submit a NDA for the drug in early 2018.
ABiC viable option for different stages severities of glaucomaWith its ability to restore the eye’s natural outflow pathway, ab-interno canaloplasty (ABiC) presents a viable option for the treatment of different stages and severities of glaucoma, according to Mark J. Gallardo, MD.
IOP fluctuations important factor in setting patients’ target pressureWhen setting a target IOP for patients with glaucoma, consideration of IOP fluctuations and the degree to which they vary is important.